Both THC and CBD significantly inhibit multiple liver enzymes (CYP450s) responsible for metabolizing roughly 60% of all prescription medications, meaning cannabis can increase blood levels of drugs you are already taking — sometimes dangerously.
Anyone using cannabis alongside prescription or OTC medications, medical cannabis patients, prescribing physicians, and pharmacists.
These CYP enzymes metabolize ~60% of all prescription drugs — and both THC and CBD inhibit multiple ones.
The Backstory
Most people who use cannabis also take other drugs. Not illicit drugs — prescription medications. SSRIs for depression. Benzodiazepines for anxiety. Blood pressure medications. Blood thinners. Pain medications. Anticonvulsants. Immunosuppressants. The average medical cannabis patient takes multiple prescription drugs.
In 2021, Shamema Nasrin and colleagues at Washington State University published two companion papers that revealed just how broadly cannabis compounds interfere with the liver enzymes that process these medications. The scope of the interference was larger, more persistent, and more clinically significant than most doctors — let alone patients — realized.
How Your Liver Processes Drugs
Your liver contains a family of enzymes called cytochrome P450 (CYP450) that metabolize — break down and deactivate — most drugs that enter your body. Different enzymes in this family handle different drugs. When one drug inhibits a CYP enzyme, it slows the metabolism of every other drug that enzyme processes. The other drugs linger longer in the bloodstream, at higher concentrations. Their effective dose increases without anyone prescribing a higher dose.
This is the mechanism behind most drug-drug interactions in medicine. It is not exotic pharmacology — it is how grapefruit juice increases the potency of certain medications (grapefruit inhibits CYP3A4). Cannabis does the same thing, but across a broader range of enzymes.
Process
How Cannabis Creates Drug Interactions
You take cannabis + a medication
Both THC and CBD enter the bloodstream and reach the liver, where they encounter the same CYP450 enzymes that process your prescription drugs.
Cannabinoids inhibit CYP enzymes
THC inhibits CYP1A2, CYP2B6, CYP2C9, CYP2D6. CBD inhibits CYP3A4, CYP2B6, CYP2C9, CYP2D6, CYP2E1. Both inhibit CYP2C19. The enzymes that would normally process your medication are now partly blocked.
Your medication builds up
Because the CYP enzymes are inhibited, your medication is metabolized more slowly. Blood levels rise above what your doctor intended when they prescribed the dose.
THC metabolites extend the window
Even after THC itself is cleared, its metabolites — 11-OH-THC and THC-COOH-glucuronide — continue inhibiting CYP enzymes. The drug interaction persists longer than the cannabis high.
Nasrin et al. (2021), Drug Metab Dispos 49(12):1070-1080
What Nasrin Found
How They Did It
Mapping the Full Scope of Cannabis-Drug Interactions
Select targets
Tested seven major CYP enzymes: CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4. These enzymes collectively metabolize roughly 60% of all prescription medications.
Also tested UGT enzymes in a companion paper, expanding the scope to phase II metabolism
Test cannabinoids + metabolites
Tested THC, CBD, CBN, and critically, the THC metabolites 11-OH-THC and THC-COOH-glucuronide. Previous studies had only tested parent compounds.
Testing metabolites was the key innovation — these circulating compounds persist long after the acute effects of cannabis resolve
Determine inhibition kinetics
For each cannabinoid-enzyme combination, determined whether inhibition was competitive, noncompetitive, or mixed-type, and measured IC50 values (the concentration at which enzyme activity is reduced by 50%).
Different inhibition types have different clinical implications — competitive inhibition is dose-dependent and can be overcome by increasing the substrate
Model clinical implications
Used static drug-drug interaction modeling to predict which interactions are most likely to be clinically significant at achievable plasma cannabinoid concentrations.
Modeling suggested pharmacokinetic interactions are most likely for drugs metabolized by CYP2B6, CYP2C9, and CYP2D6
Nasrin et al. (2021), Drug Metab Dispos 49(12):1070-1080 and 49(12):1081-1089
~60%
of all prescription medications are metabolized by the CYP enzymes that THC and CBD inhibit. This is not a marginal finding. It means that for the majority of prescription drugs, cannabis has the potential to alter how your body processes them. The clinical significance varies — some interactions are trivial, others are potentially dangerous — but the breadth of the potential interaction is striking.
For context, the FDA's drug interaction warning for grapefruit juice — one of the most well-known food-drug interactions — involves primarily one enzyme (CYP3A4). Cannabis inhibits at least seven.
Nasrin et al. (2021)
The Highest-Risk Interactions
Not all drug interactions are clinically significant. The concern is greatest for medications with a narrow therapeutic index — drugs where the difference between an effective dose and a toxic dose is small.
- Blood Thinners (Warfarin) high
Mandatory disclosure to prescriber; INR monitoring required
Warfarin is metabolized by CYP2C9, which THC inhibits. Cannabis use has been documented to increase INR (a measure of blood thinning) to dangerous levels. Case reports of bleeding events exist.
- Immunosuppressants (Transplant) high
Mandatory disclosure; drug level monitoring essential
Tacrolimus and cyclosporine are metabolized by CYP3A4, which CBD potently inhibits. For transplant patients, elevated immunosuppressant levels can cause kidney damage, while subtherapeutic levels risk organ rejection.
- Opioids high
Disclosure required; dose adjustment may be needed
Opioids metabolized by CYP3A4 and CYP2D6 can accumulate. Combined with cannabis's own sedating effects, this creates additive CNS depression risk. Conversely, CYP2D6 inhibition could reduce conversion of codeine to its active form.
- Benzodiazepines moderate
Disclosure recommended; monitor for excess sedation
Many benzodiazepines are CYP3A4 substrates. Cannabis inhibition can slow their metabolism, leading to increased sedation and cognitive impairment.
- SSRIs/Antidepressants moderate
Disclosure recommended; monitor for increased side effects
Metabolized by various CYP enzymes (CYP2D6, CYP2C19, CYP3A4). Cannabis can increase SSRI blood levels, potentially amplifying both effects and side effects including serotonin syndrome risk.
- Blood Pressure Medications moderate
Disclosure recommended; monitor blood pressure
Some antihypertensives are CYP-metabolized. Combined with cannabis's own cardiovascular effects, the interaction could cause excessive blood pressure changes.
- NSAIDs (Ibuprofen) low
Low concern at normal doses; high-dose or chronic use warrants awareness
Ibuprofen is primarily metabolized by CYP2C9. While interaction is possible, the wide safety margin of NSAIDs at normal doses makes clinical significance unlikely for most users.
Nasrin et al. (2021); clinical pharmacology references
The Metabolite Discovery
The finding that sets Nasrin's work apart from earlier drug interaction studies is the metabolite data. Previous research focused on THC and CBD as parent compounds. Nasrin showed that 11-OH-THC (the active metabolite that makes edibles feel different) and THC-COOH-glucuronide (the metabolite detected in standard drug tests) are also significant CYP inhibitors.
What You Should Do
The practical guidance is straightforward:
- Tell your doctor if you use cannabis. This is the single most important action. Many patients don't disclose because of stigma, but your doctor cannot manage drug interactions they don't know about.
- Tell your pharmacist too. Pharmacists screen for drug interactions as part of their standard workflow, but they can only include cannabis if they know about it.
- Don't adjust medications on your own. If you suspect an interaction, consult your prescriber before changing anything. Stopping a medication abruptly can be more dangerous than the interaction itself.
- Know your high-risk medications. If you take warfarin, immunosuppressants, opioids, or medications with narrow therapeutic windows, disclosure is not optional — it is a safety requirement.
- CBD products carry the same risk. Many consumers assume that CBD, being non-psychoactive, is pharmacologically inert. Nasrin's data shows CBD is a more potent CYP3A4 inhibitor than THC. This is especially relevant for the millions of people taking OTC CBD supplements alongside prescription medications.
Does cannabis interact with SSRIs?
Potentially yes. Most SSRIs are metabolized by CYP2D6, CYP2C19, or CYP3A4 — all of which THC or CBD inhibit. This could increase SSRI blood levels and amplify both therapeutic effects and side effects. Our full guide on cannabis and antidepressants covers specific SSRIs and risk levels. The interaction is manageable with medical supervision, but disclosure to your prescriber is essential.
Is CBD safer than THC for drug interactions?
No — in fact, CBD is a more potent inhibitor of CYP3A4, the single most important drug-metabolizing enzyme (responsible for ~50% of drug metabolism). This is why Epidiolex, the FDA-approved CBD product, carries explicit drug interaction warnings in its prescribing information. The widespread perception that CBD is pharmacologically inert because it is non-psychoactive is incorrect.
How long do cannabis drug interactions last?
Longer than the high. THC's acute effects last hours, but Nasrin showed that THC metabolites — which persist in the body for days to weeks — also inhibit CYP enzymes. For chronic users with persistent metabolite levels, the interaction may be ongoing. Even occasional users should be aware that the interaction window extends beyond the subjective effects.
Should I stop using cannabis if I take prescription medications?
Not necessarily — many interactions are clinically mild and manageable. The essential step is disclosure to your prescriber so they can monitor for interactions, adjust doses if needed, or recommend alternatives. Some medication-cannabis combinations require extra monitoring (e.g., INR checks for warfarin), while others may need dose adjustments. Never stop medications without medical guidance.
Related Research
Understanding Cannabis Pharmacology and Safety
Nasrin's work reveals the clinical pharmacology that makes cannabis a more complex drug than most consumers realize.
11-OH-THC: pharmacology, disposition, and metabolism
Lemberger, Crabtree & Rowe (1972)
The discovery that THC's liver metabolite is pharmacologically active — the same metabolite that Nasrin showed also inhibits CYP enzymes
CBD for Dravet syndrome (NEJM)
Devinsky et al. (2017)
Epidiolex clinical trials documented CBD-drug interactions with clobazam (a benzodiazepine) — real-world confirmation of Nasrin's enzyme inhibition data
CBD as an antipsychotic
Leweke et al. (2012)
CBD's mechanism involves anandamide signaling via FAAH inhibition — Piomelli was a co-author, connecting CBD pharmacology to broader endocannabinoid science
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids
Pertwee et al. (2008)
Comprehensive cannabinoid pharmacology — the receptor-level science that complements Nasrin's metabolic enzyme findings
NASEM: The Health Effects of Cannabis
National Academies (2017)
The comprehensive review that flagged drug interactions as an area requiring more research — Nasrin's papers delivered that research
What the researchers found
THC inhibits CYP1A2, CYP2B6, CYP2C9, CYP2D6. CBD inhibits CYP3A4, CYP2B6, CYP2C9, CYP2D6, CYP2E1. Both show mixed inhibition of CYP2C19. THC metabolites (11-OH-THC, THC-COOH-glucuronide) are also significant inhibitors.
Why it matters
With millions of people using cannabis alongside prescription medications — including virtually all medical cannabis patients — the clinical implications are enormous. Cannabis does not just affect you; it affects how your body processes every other drug you take.
How the study worked
In vitro inhibition assays using pooled human liver microsomes and baculovirus-expressed recombinant CYP enzymes. IC50 determination and inhibition kinetics (competitive, noncompetitive, mixed-type) for each cannabinoid-enzyme combination. Static drug-drug interaction modeling.
Who was studied
In vitro study using human liver microsomes and recombinant CYP enzymes
What this study cannot tell us
In vitro study using liver microsomes — the clinical significance of each interaction depends on achievable tissue concentrations of cannabinoids in actual cannabis users. Some inhibition effects observed at concentrations higher than typical plasma levels. In vivo human pharmacokinetic studies are needed to confirm clinical relevance of each specific interaction.
How to read the evidence
Strong in vitro evidence from a rigorous pharmacokinetic study published in the flagship drug metabolism journal. The enzyme inhibition is clearly demonstrated. Clinical relevance of each specific interaction requires confirmation through in vivo human studies.
When this study was published
Published December 2021 — recent and highly relevant as cannabis-drug interaction awareness remains low among consumers and many clinicians.
The bigger picture
This study fundamentally changed the understanding of cannabis-drug interaction risk. Previous research focused on THC and CBD alone; Nasrin showed that metabolites are also potent inhibitors, meaning the interaction window extends well beyond the acute effects of cannabis. Combined with the companion UGT paper, the scope of potential interactions is much broader than previously recognized.
Questions still open
- ["At what cannabis doses do clinically significant CYP inhibition effects occur?","Are chronic cannabis users at greater risk for drug interactions due to persistent metabolite levels?","Should routine cannabis screening be required before prescribing CYP3A4-metabolized medications?","How do different routes of administration affect the magnitude of drug interactions?"]
Common questions
Which medications interact with cannabis?
Is CBD or THC worse for drug interactions?
Should I stop taking my medications if I use cannabis?
Does this mean cannabis is dangerous with all medications?
Read the original research
Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions
Drug Metabolism and Disposition
The flagship journal of the American Society for Pharmacology and Experimental Therapeutics for drug metabolism research.
Citation
Nasrin, Shamema; Watson, Christy J W; Perez-Paramo, Yadira X; Lazarus, Philip. (2021). Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions. Drug Metabolism and Disposition. https://doi.org/10.1124/dmd.121.000442